SpectRx cancer assay
This article was originally published in The Gray Sheet
Executive Summary
Pivotal clinical trials for the non-invasive cervical cancer detection device will begin by early 2003, SpectRx announces April 15. Clinical results indicate that the third-generation device detects 17% more high-grade pre-cancer compared to thin-layer Pap tests and 28% more than traditional Pap tests. The device also boasts a sensitivity of 92% and specificity of 80%, versus sensitivity of 76% and specificity of 80% for the thin-layer Pap test when compared to colposcopy and histopathology, the firm claims (1"The Gray Sheet" April 17, 2000, p. 18)...
You may also be interested in...
SpectRx
Pivotal trials of firm's non-invasive, biophotonic cervical cancer test are expected to begin by early 2003. SpectRx announces July 9 that protocols have been submitted to FDA. Preliminary data from a National Cancer Institute study in 274 women showed a prototype test detected 15% more high-grade "pre-cancers" than standard Pap tests, and could potentially cut by half the number of false positives detected by human papilloma virus (HPV) tests. Previously, the device demonstrated a sensitivity of 92% and specificity of 80%, versus sensitivity of 76% and specificity of 80% for the thin-layer Pap test, according to SpectRx (1"The Gray Sheet" April 22, 2002, In Brief)...
SpectRx/Welch Allyn Cervical Cancer Detection PMA Expected By 2002
Premarket approval application submission for a non-invasive cervical cancer detection system co-developed by SpectRx and Welch Allyn will occur in late 2001 or early 2002, SpectRx says.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.